brigatinib | Cancer Search

Details 3 Related Guidelines / Approvals

type

NCCN Guideline

nccn category

2A

biomarker

biomarker

ALK Fusion

condition

condition

Non-Small Cell Lung Carcinoma

settings

settings

Advanced

settings

Metastatic

settings

Subsequent line

drugs

drug

brigatinib

drug types

drug

targeted therapy

references

link

Non-Small Cell Lung Cancer (NCCN Guidelines) [3.2022]

source

NCCN

brigatinib

biomarker

ALK Fusion

condition

Non-Small Cell Lung Carcinoma

disease state

Metastatic

drug

brigatinib

drug type

targeted therapy

brigatinib

biomarker

ALK Fusion

condition

Non-Small Cell Lung Carcinoma

disease state

Advanced, +1 more state

therapeutic contexts

First line

drug

brigatinib

drug type

targeted therapy

brigatinib

biomarker

ALK Fusion

condition

Inflammatory Myofibroblastic Tumor

drug

brigatinib

drug type

targeted therapy

3 therapies
Page 1 of 1